BetterLife CEO Discusses Synairgen’s Interferon Breakthrough Treatment
July 28, 2020 08:00 ET
|
BetterLife Pharma
New York City, July 28, 2020 (GLOBE NEWSWIRE) -- The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company currently preparing a potential...
BetterLife CEO Discusses Merger, Planned Interferon Treatment Trials and Potential Subsequent FDA Emergency Use Authorization
July 23, 2020 08:00 ET
|
BetterLife Pharma
New York City, July 23, 2020 (GLOBE NEWSWIRE) -- The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRD) (CSE:BETR), an emerging biotechnology company currently preparing its own...
Interferon Treatment Trial 'a Major Breakthrough' Against the Pandemic
July 21, 2020 08:00 ET
|
BetterLife Pharma
NEW YORK CITY, July 21, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (OTCQB:BETRD) (CSE:BETR) has been a strong advocate and defender of using interferons as...
Respiratory Care Devices Market to Reach $21.3billion by 2022 at 7.4% CAGR, Says AMR
July 02, 2020 10:46 ET
|
Allied Market Research
Portland, OR, July 02, 2020 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global respiratory care devices market was valued at $12.89 billion in 2015, and is...
BetterLife Pharma (OTCB:BETRD) CEO Discusses Using Interferons to Defeat ‘Truly Evil Virus’
July 02, 2020 08:00 ET
|
BDA International
New York City, July 02, 2020 (GLOBE NEWSWIRE) -- The CEO of BetterLife Pharma (OTCQB:BETRD) (CSE: BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development company, recently...
Topical Pain Relief Market to Reach $13,276 million by 2025 at 7.4% CAGR, Says AMR
June 24, 2020 11:10 ET
|
Allied Market Research
Portland, OR, June 24, 2020 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the topical pain relief market was valued at $7,481 million in 2017, and is expected to...
BetterLife Pharma (OTCQB:BETRF) Looks to Immune Response Drug Interferon a2b as Potential Therapeutic for COVID-19
June 19, 2020 07:56 ET
|
BDA International
New York City, June 19, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma (OTCQB:BETRF) (CSE: BETR) (FRANKFURT: NPAT), an emerging clinical stage pharmaceutical development company, announced recently that...
eFFECTOR’s Zotatifin Demonstrates in vitro Anti-SARS-CoV-2 Activity in Independent International Study Reported in Peer-Reviewed Journal Nature
April 30, 2020 09:00 ET
|
eFFECTOR Therapeutics
SAN DIEGO, April 30, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., today announced that preliminary results from an independent preclinical study showed that oncology product candidate...
Revolution Medicines Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 18, 2020 16:01 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive...
Dr. Adam Friedman to Present Keynote at Dermatology Fall Update
November 07, 2019 09:00 ET
|
Zylö Therapeutics
GREENVILLE, SC, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that its scientific advisor, Adam Friedman MD,...